PIETRASANTA, DANIELA
 Distribuzione geografica
Continente #
EU - Europa 94
NA - Nord America 58
AS - Asia 19
Totale 171
Nazione #
US - Stati Uniti d'America 56
IE - Irlanda 46
SE - Svezia 23
DE - Germania 11
HK - Hong Kong 10
SG - Singapore 9
IT - Italia 6
CZ - Repubblica Ceca 5
CA - Canada 2
FR - Francia 2
GB - Regno Unito 1
Totale 171
Città #
Dublin 46
Hong Kong 10
Chandler 9
Boardman 7
Bremen 6
Lawrence 6
Princeton 6
Singapore 6
Brno 5
Somaglia 4
Gunzenhausen 2
Cagliari 1
Frankfurt am Main 1
Munich 1
Ottawa 1
Palermo 1
Santa Clara 1
Toronto 1
Totale 114
Nome #
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 34
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 32
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 30
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 27
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 26
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 25
Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real‐World” study 4
Totale 178
Categoria #
all - tutte 1.862
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.862


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202218 0 0 0 0 0 0 0 0 0 0 6 12
2022/2023107 6 6 10 0 7 7 0 12 50 1 3 5
2023/202435 4 1 3 0 3 0 10 0 0 0 3 11
2024/202518 5 0 6 1 6 0 0 0 0 0 0 0
Totale 178